The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.
Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...
In recent years, the conversation around artificial intelligence (AI) in healthcare has intensified, especially in the realm of drug discovery. Reshma Kewalramani, the CEO of Vertex Pharmaceuticals, ...
StockStory.org on MSN
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...
Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Pove was generally safe and well tolerated with adverse events (AEs) that were mostly mild or moderate in severity. There were no serious adverse events related to povetacicept. The safety data is ...
V2X, Inc. (NYSE:VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.25 million shares ...
Vertex (NASDAQ: VERX) delivered a split result this morning that left investors parsing mixed signals. The tax technology ...
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback